Bufexamac
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329211

CAS#: 2438-72-4

Description: Bufexamac, also known as Droxaryl and CP-1044-J-3, is a benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. Bufexamac is used to treat various skin disorders.


Chemical Structure

img
Bufexamac
CAS# 2438-72-4

Theoretical Analysis

MedKoo Cat#: 329211
Name: Bufexamac
CAS#: 2438-72-4
Chemical Formula: C12H17NO3
Exact Mass: 223.12
Molecular Weight: 223.272
Elemental Analysis: C, 64.55; H, 7.67; N, 6.27; O, 21.50

Price and Availability

Size Price Availability Quantity
1g USD 150
2g USD 250
5g USD 450
Bulk inquiry

Synonym: Bufexamac; CP-1044-J-3; CP 1044 J 3; CP1044J3; Droxaryl; Parfenac

IUPAC/Chemical Name: 2-(4-butoxyphenyl)-N-hydroxyacetamide

InChi Key: MXJWRABVEGLYDG-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)

SMILES Code: O=C(NO)CC1=CC=C(OCCCC)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 223.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Pan Y, Nixon R. Allergic contact dermatitis to topical preparations of bufexamac. Australas J Dermatol. 2012 Aug;53(3):207-10. doi: 10.1111/j.1440-0960.2012.00876.x. PubMed PMID: 22881467.

2: Seto Y, Ochi M, Igarashi N, Inoue R, Oishi A, Toida T, Yamada S, Onoue S. In vitro photobiochemical characterization of sulfobutylether-β-cyclodextrin formulation of bufexamac. J Pharm Biomed Anal. 2011 Jun 1;55(3):591-6. doi: 10.1016/j.jpba.2011.02.025. PubMed PMID: 21429689.

3: Nakada T, Matsuzawa Y. Allergic contact dermatitis syndrome from bufexamac for nursing infant. Dermatitis. 2012 Jul-Aug;23(4):185-6. doi: 10.1097/DER.0b013e318260d774. PubMed PMID: 22828265.

4: Waltermann K, Marsch WCh, Kreft B. [Bufexamac-induced pigmented purpuric eruption]. Hautarzt. 2009 May;60(5):424-7. doi: 10.1007/s00105-008-1656-2. German. PubMed PMID: 19093092.

5: Fukuda H, Sato Y, Usami N, Yokouchi Y, Mukai H. Contact dermatitis caused by bufexamac sparing the eruption of herpes zoster. J Dermatol. 2012 Apr;39(4):405-7. doi: 10.1111/j.1346-8138.2011.01261.x. PubMed PMID: 21950459.

6: Schnuch A, Gefeller O, Uter W. [A common and insidious side-effect: allergic contact dermatitis caused by bufexamac used in the treatment of dermatitis. Results from the Information Network of Departments of Dermatology (IDVK)]. Dtsch Med Wochenschr. 2005 Dec 16;130(50):2881-6. German. PubMed PMID: 16342011.

7: Uter W, Schnuch A. EMA revokes marketing authorization for bufexamac. Contact Dermatitis. 2011 Apr;64(4):235-6. doi: 10.1111/j.1600-0536.2011.01883.x. PubMed PMID: 21392031.

8: Marttinen PH, Raulo SM, Suominen MM, Tulamo RM. Changes in MMP-2 and -9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac. J Vet Med A Physiol Pathol Clin Med. 2006 Aug;53(6):311-8. PubMed PMID: 16901276.

9: Xiao Q, Dong N, Yao X, Wu D, Lu Y, Mao F, Zhu J, Li J, Huang J, Chen A, Huang L, Wang X, Yang G, He G, Xu Y, Lu W. Bufexamac ameliorates LPS-induced acute lung injury in mice by targeting LTA4H. Sci Rep. 2016 Apr 29;6:25298. doi: 10.1038/srep25298. PubMed PMID: 27126280; PubMed Central PMCID: PMC4850449.

10: Trommer H, Plätzer M, Raith K, Wohlrab W, Podhaisky HP, Neubert RH. Examinations of the antioxidative properties of the topically administered drug bufexamac reveal new insights into its mechanism of action. J Pharm Pharmacol. 2003 Oct;55(10):1379-88. PubMed PMID: 14607020.

11: Belhadjali H, Ghannouchi N, Njim L, Mohamed M, Moussa A, Bayou F, Chakroun M, Zakhama A, Zili J. Acute generalized exanthematous pustulosis induced by bufexamac in an atopic girl. Contact Dermatitis. 2008 Apr;58(4):247-8. doi: 10.1111/j.1600-0536.2007.01271.x. PubMed PMID: 18353041.

12: Proske S, Uter W, Schnuch A, Hartschuh W. [Severe allergic contact dermatitis with generalized spread due to bufexamac presenting as the "baboon" syndrome]. Dtsch Med Wochenschr. 2003 Mar 14;128(11):545-7. German. PubMed PMID: 12635026.

13: Suominen MM, Tulamo RM, Anttila MO, Sankari SM, Király K, Lapveteläinen T, Helminen HJ. Effects of intra-articular injections of bufexamac suspension in healthy horses. Am J Vet Res. 2001 Oct;62(10):1629-35. PubMed PMID: 11592331.

14: Arikawa J, Okabe S, Kaneko T. Allergic contact dermatitis with spreading over extensive regions due to topical use of 5% bufexamac ointment. J Dermatol. 2004 Feb;31(2):136-8. PubMed PMID: 15160871.

15: Suominen MM, Tulamo RM, Puupponen LM, Sankari SM. Effects of intra-articular injections of bufexamac suspension on amphotericin B-induced aseptic arthritis in horses. Am J Vet Res. 1999 Dec;60(12):1467-73. PubMed PMID: 10622153.